This is a firm fixed price delivery order awarded by the Department of Veterans Affairs (VA) to Dompe U.S. Inc., a foreign-owned pharmaceutical manufacturer, to provide Oxervate (cenegermin-bkbj) 0.002% ophthalmic solution. The $39,774.12 order was placed against Dompe's existing General Services Administration (GSA) Pharmaceutical and Drugs Schedule contract (FSS-61-IB). Oxervate is an ophthalmic product used to treat neurotrophic keratitis. This order does not have a set-aside designation. Dompe also holds a $2.4 million Blanket Purchase Agreement with the VA National Acquisition Center specifically for Oxervate, as well as a $5 million FSS Schedule contract to provide pharmaceuticals more broadly. These contracts allow the VA to efficiently procure critical ophthalmic medications to meet the healthcare needs of veterans.
Generated 2/6/25, 9:13 AM